This study tests if adding **atebimetinib** to usual cancer drugs **gemcitabine** and **nab-paclitaxel** helps patients with **metastatic pancreatic adenocarcinoma** live longer. Metastatic means the cancer has spread. Pancreatic adenocarcinoma is a type of cancer starting in the pancreas, an organ that helps digest food. Patients will be placed randomly into two groups: one group will get atebimetinib with gemcitabine and nab-paclitaxel, while the other group will get just gemcitabine and nab-paclitaxel. **Randomized** means the computer chooses your group by chance, and **open-label** means both doctors and patients know the treatment you're getting.

**Key Points:**

• **Length**: Study duration varies; treatment continues until it is no longer beneficial.
• **Visits Needed**: Frequent visits for treatment and monitoring.
• **Risks**: Potential side effects from treatments; discuss these with your doctor.

To join, you must be at least 18, have no prior cancer treatment for pancreatic adenocarcinoma, and be able to take pills by mouth. You also need to have cancer that can be measured and have good organ function. You cannot join if you have other types of pancreatic cancer or brain metastases.